Batavia Biosciences to Accelerate CAN-3110 Production with Candel Therapeutics

• Batavia Biosciences has partnered with Candel Therapeutics to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors.

• Batavia Biosciences will use its HIP-Vax technology to develop a manufacturing process for Candel Therapeutics, enabling the production of CAN-3110 for toxicity studies and establishing a GMP-compatible process for upcoming clinical trials.

• CAN-3110 recently received FDA Fast-Track Designation to speed up the development of this promising immunotherapy candidate to improve overall survival in patients with recurrent high-grade glioma (HGG).

Batavia Biosciences, a contract development and manufacturing organization (CDMO), has announced a partnership with Candel Therapeutics, a clinical stage biopharmaceutical company. The collaboration aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).

Batavia Biosciences will leverage its HIP-Vax technology to develop a highly intensified, scalable, and robust manufacturing process for Candel Therapeutics. This work will facilitate the production of CAN-3110 for toxicity studies and establish a Good Manufacturing Practice (GMP)-compatible process for the forthcoming clinical trials.

Peter Abbink, PhD, Managing Director at Batavia Biosciences Inc., expressed his pleasure at the partnership. He said, “We are very pleased that Candel Therapeutics decided to contract Batavia Biosciences based on our proven track record with developing highly intensified processes resulting in low cost of goods. We are honored to collaborate with Candel Therapeutics, a biopharmaceutical company with extensive scientific expertise in working to develop solutions for patients with brain tumors.”

CAN-3110 recently received FDA Fast-Track Designation, a significant step towards speeding up the development of this promising immunotherapy candidate. The aim is to improve overall survival in patients with recurrent high-grade glioma (HGG), one of the most aggressive malignancies for which there is currently no cure available. This represents a significant and urgent unmet medical need.

David Maheu, Vice President, Viral Vector Process & Analytical Development at Candel Therapeutics, expressed his confidence in the partnership. He remarked, “Candel is excited to be partnering with Batavia, an organization we consider to be best in class with respect to HSV bioprocessing as well as our chosen manufacturing platform. We’re confident this relationship will ensure CAN-3110 is produced in a manner that ensures safe and effective medicine is available to every patient in need of this potentially life-changing therapy.”